Results Presentation and DoseMeRx Update

RNS Number : 5994N

Physiomics PLC

30 September 2021

 

30 September 2021

Physiomics plc

("Physiomics") or ("the Company")

Presentation of results for the year ended 30 June 2021 and update on collaboration with TabulaRasa Healthcare's DoseMeRx subsidiary

Physiomics plc (AIM: PYC), the consultancy using mathematical models to support the development of drug treatment regimens and personalised medicine solutions today made a presentation regarding its final results for the year ended 30 June 2021, using the Investor Meet Company platform.  The slide deck used in the presentation will be posted on the Company's website at https://www.physiomics.co.uk/resources/ and a recording of the presentation, together with the subsequent Q&A, will be made available on the Investor Meet Company platform and can be accessed by registering or logging on at https://www.investormeetcompany.com/physiomics-plc/register-investor .

During the presentation, Dr Jim Millen, CEO, noted that the integration of the Company's personalised dosing software tool into TabulaRasa Healthcare's subsidiary DoseMeRx's existing platform had been recently completed and that a period of user testing would take place over the next few months.  Further announcements relating to this collaboration will be made when appropriate.  This news comes shortly after the Company's announcement on 21 September 2021 of the recruitment of the first patient into its PARTNER study which is being run by Portsmouth Hospitals University NHS Trust and which is expected to generate further data for the validation and development of the Company's personalised dosing software tools.

Enquiries:

Physiomics plc 

Dr Jim Millen, CEO

[phone]

Hybridan LLP (broker)

Claire Louise Noyce

[phone]

Strand Hanson Ltd (NOMAD)

James Dance & James Bellman

[phone]

Notes to Editor

About Physiomics

Physiomics plc (AIM: PYC) is an oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions. The Company's Virtual Tumour™ technology uses computer modelling to predict the effects of cancer drugs and treatments to improve the success rate of drug discovery and development projects while reducing time and cost. The predictive capability of Physiomics' technologies have been confirmed by over 80 projects, involving over 40 targets and 70 drugs, and has worked with clients such as Merck KGaA, Astellas, Merck & Co and Bicycle Therapeutics.

 

END

 

 

MSCFLFVVASIIVIL